TOP-25 rating of corporations on the Russian pharmaceutical market by sales value had no major changes in 2014
OTCPharm lost its place in the TOP-10 list, and there are now no Russian corporations among the TOP-10 players. Pharmstandard, however, kept its place in the rating despite a small decrease in the share.
ТОР25 Corporations on the Russian pharmaceutical market by value share (rubles) in 2014 (Excluding Food Supplements), % |
|||||
Rating |
Corporation |
Share |
Sales Growth |
||
2014 |
2013 |
2014 |
2013 |
2014/2013 |
|
1 |
1 |
Novartis* |
5,46 |
5,79 |
5 |
2 |
2 |
Sanofi** |
5,25 |
5,53 |
6 |
3 |
3 |
Bayer Healthcare |
3,68 |
3,74 |
10 |
4 |
5 |
Takeda |
3,12 |
3,03 |
15 |
5 |
4 |
Teva |
3,07 |
3,30 |
4 |
6 |
8 |
Johnson & Johnson |
2,93 |
2,84 |
15 |
7 |
7 |
Servier |
2,91 |
2,94 |
11 |
8 |
6 |
Roche |
2,82 |
2,94 |
7 |
9 |
11 |
Pfizer |
2,49 |
2,16 |
29 |
10 |
9 |
Berlin-Chemie/Menarini |
2,39 |
2,57 |
4 |
11 |
12 |
Gedeon Richter |
2,15 |
2,13 |
13 |
12 |
13 |
Abbott |
2,09 |
2,12 |
10 |
13 |
10 |
OTCPharm |
2,07 |
2,32 |
0,1 |
14 |
14 |
Stada |
1,95 |
2,10 |
4 |
15 |
15 |
Merck Sharp & Dohme |
1,88 |
1,97 |
7 |
16 |
17 |
KRKA |
1,76 |
1,76 |
12 |
17 |
16 |
Boehringer Ingelheim |
1,71 |
1,78 |
8 |
18 |
18 |
GlaxoSmithKline |
1,64 |
1,66 |
11 |
19 |
19 |
AstraZeneca |
1,59 |
1,56 |
15 |
20 |
20 |
Astellas Pharma |
1,51 |
1,53 |
11 |
21 |
21 |
Dr Reddys |
1,29 |
1,30 |
11 |
22 |
22 |
Pharmstandard |
1,28 |
1,29 |
11 |
23 |
23 |
Actavis |
1,13 |
0,94 |
35 |
24 |
24 |
Valenta |
1,07 |
0,92 |
29 |
25 |
25 |
Reckitt Benckiser |
0,88 |
0,86 |
14 |
ТОР25 Total |
58,12 |
59,08 |
|
* Including Sandoz sales
** Including Zentiva sales
Source: IMS Health
TOP-25 corporations account for 58.12% of the market in value, which is slightly less than in 2013. TOP-25 corporations segment grew 10% in 2014, which is 2% below the overall market growth rate of 12%. This can be attributed to increasing value shares of corporations outside the TOP-25 list.
Source: Pharmvestnik